Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Wright

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
Emerging Infectious Diseases|December 2, 2005
Methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci co-colonizationJon P Furuno, Eli N Perencevich, Judith A Johnson, et al.
Emerging Infectious Diseases|March 21, 2007
Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalizationRebecca H Sunenshine, Marc-Oliver Wright, Lisa L Maragakis, et al.
Lancet (London, England)|April 18, 2015
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trialPeter Hillmen, Tadeusz Robak, Ann Janssens, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
Emerging Infectious Diseases|December 2, 2005
Methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci co-colonizationJon P Furuno, Eli N Perencevich, Judith A Johnson, et al.
Emerging Infectious Diseases|March 21, 2007
Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalizationRebecca H Sunenshine, Marc-Oliver Wright, Lisa L Maragakis, et al.
Lancet (London, England)|April 18, 2015
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trialPeter Hillmen, Tadeusz Robak, Ann Janssens, et al.
Pageof 9